Spero logo.jpg
Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update
November 14, 2022 16:05 ET | Spero Therapeutics, Inc.
Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which Spero receives $66 million upfront, and a $9 million direct equity investment in Spero shares of...
Spero logo.jpg
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr
November 08, 2022 08:05 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero logo.jpg
Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
November 07, 2022 08:05 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero logo.jpg
Spero Therapeutics to Present Data at IDWeek 2022
October 19, 2022 08:05 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero logo.jpg
Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program
October 03, 2022 08:05 ET | Spero Therapeutics, Inc.
Event is taking place on Thursday, October 6th at 11:30 a.m. ET Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH (Division of Infectious Disease, OHSU Medical...
Spero logo.jpg
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
September 22, 2022 02:00 ET | Spero Therapeutics, Inc.
The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero Therapeutics receives $66 million upfront, with potential...
Spero logo.jpg
Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer
September 15, 2022 16:05 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO). “Kamal...
Spero.jpg
Spero Therapeutics to Present at Upcoming Investor Conference
September 07, 2022 08:05 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration
September 06, 2022 08:05 ET | Spero Therapeutics, Inc.
Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr FDA feedback indicates positive results from a single additional Phase 3 clinical trial in patients...
Spero.jpg
Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update
August 10, 2022 16:05 ET | Spero Therapeutics, Inc.
Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expected in 4Q 2022 Initiation of a Phase 2 Cross-indication Resistant Pathogen...